公司评级与市场表现 - Jefferies于2025年9月29日将MoonLake Immunotherapeutics评级从"买入"下调至"持有" 反映保守观点 [2] - 评级下调时股价为6 14美元 较历史高点大幅下跌 [2] - 股价当前报6 25美元 日内波动区间5 96-7 13美元 年内峰值62 75美元 最低点5 95美元 [5] 临床试验进展 - 第3阶段VELA-1和VELA-2试验第16周结果触发市场负面反应 [3] - 试验采用HiSCR75终点指标 评估sonelokimab对脓肿和炎症结节数量减少75%的效果 [3] - 试验设计包含838名患者 120mg剂量组与安慰剂对照 第16周后所有患者接受120mg剂量直至第48周 最终评估在第52周 [4] 股价与市值变动 - 股价累计下跌约89 93% 相当于55 75美元跌幅 [4] - 公司当前市值约3 9657亿美元 日交易量达7672万股 [5] 行业竞争定位 - MoonLake专注于炎症性疾病创新疗法开发 主要产品sonelokimab针对特定炎症适应症 [1] - 公司在免疫治疗领域与多家生物技术企业存在激烈竞争 [1]

NEW YORK, Sept. 29, 2025 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces an investigation into MoonLake Immunotherapeutics (NASDAQ: MLTX) for potential violations of the federal securities laws. If you invested in MoonLake, you are encouraged to obtain additional information by visiting: https://www.bfalaw.com/cases/moonlake-immunotherapeutics. Why Is MoonLake being Investigated? MoonLake is a clinical stage biotechnology company focusing on therapies to address inflamma ...

PresentationMatthias BodenstedtChief Financial Officer Welcome, everyone. Good morning, good afternoon. Thank you for joining today's webcast. My name is Matthias Bodenstedt, I'm the Chief Financial Officer of MoonLake Immunotherapeutics. As usual, I'm joined here by our Co-Founder and CSO, Kristian Reich; our Co-Founder and CEO, Jorge da Silva. We are also honored to be joined today by Professor Alexa Kimball, a leading [indiscernible] in HS. We will go through the data and then look forward to the thought ...

公司股价表现 - MoonLake Immunotherapeutics股价跌至624美元 跌幅达8993% [1][6] - KALA BIO股价跌至213美元 跌幅达8882% [2][6] - IO Biotech股价跌至035美元 跌幅达7731% [3][6] - Maris-Tech股价跌至022美元 跌幅达7116% [4] 公司特定事件 - MoonLake Immunotherapeutics面临律师事务所潜在索赔调查 [1] - KALA BIO停止特定眼病实验性治疗药物开发 [2] - IO Biotech遭FDA建议不基于IOB-013临床试验数据提交生物制剂许可申请 将进行重组并裁员约50% [3] - Maris-Tech作为数字音视频硬件软件解决方案提供商 可能受行业技术升级或竞争压力影响 [4] 行业特征 - 生物制药与技术行业公司出现显著股价波动 [5] - 市场情绪、行业趋势及公司特定发展是影响股价的关键因素 [5]

About this content About Sean Mason Sean Mason is a Senior Journalist at Proactive, having researched and written about Canadian and US equities for 20 years. Sean graduated from the University of Toronto with a BA in history and economics and has also passed the Canadian Securities Course. He previously worked at Investors Digest of Canada, Stockhouse, and SmallCapPower.com. Read more About the publisher Proactive financial news and online broadcast teams provide fast, accessible, informative and action ...

MoonLake Immunotherapeutics‘ (NASDAQ: MLTX) stock price fell off a cliff Monday after it reported week-16 results from its Phase 3 VELA-1 and VELA-2 trials. The trials used HiSCR75—a 75% reduction in abscess and inflammatory nodule count with no increase in abscesses or draining tunnels—as the primary endpoint.Key secondary endpoints included HiSCR50 response rates and improvements in Dermatology Quality of Life Index (DLQI) scores, reflecting patient, physician, and regulatory priorities.Also Read: Sanofi ...

NEW YORK--(BUSINESS WIRE)---- $MLTX #ClassAction--Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against MoonLake Immunotherapeutics ("MoonLake†or the "Company†) (NASDAQ: MLTX). Faruqi & Faruqi is a leading national securities law firm with offices in New York, Pennsylvania, California and Georgia. The firm has recovered hundreds of millions of dollars for investors since its founding in 1995. See www.faruqilaw.com. MoonLake Immunotherapeutics saw its share ...

BOSTON, Sept. 29, 2025 (GLOBE NEWSWIRE) -- Block & Leviton is investigating MoonLake Immunotherapeutics (Nasdaq: MLTX) for potential securities law violations. Investors who have lost money in their MoonLake Immunotherapeutics investment should contact the firm to learn more about how they might recover those losses. For more details, visit https://blockleviton.com/cases/mltx. What is this all about? Shares of MoonLake Immunotherapeutics fell more than 85% in pre-market trading on September 29 after the com ...

突然"爆雷"！ 周一美股，市值近40亿美元（约合人民币285亿元）的生物技术公司MoonLake暴跌89%。此前，该公司发布的 一款实验性皮肤病药物的Ⅲ期临床试验结果远低于市场预期。随后，加拿大皇家银行将其目标价从67美元大幅 下调至10美元。Stifel将其目标价从77美元下调至13美元。 | us MoonLake Immunotherape ... (1 | | | (Ai) [7 Q | | | | --- | --- | --- | --- | --- | --- | | MLTX | | | | | | | 今开 6.960 最高 6.657 | | 7.130 最低 | | 6.560 | | | -89.26% -55.333 快手 | 62.71% | 总量 4028万股 金额 | | 2.91亿 | | | 昨日收 61.990 总值受 | 4.28亿 市图 M | -2.43 | | 更多 | | | 6.940 -55.050 -88.80% 盘前 | | | 09:30 美东 V | | | | Q) 三季报预披露: 于2025-11-06 披露 2025 财年三季报 (数 ... ...

CANADA - 2025/06/03: In this photo illustration, the MoonLake Immunotherapeutics (Moon Lake) logo is seen displayed on a smartphone screen. (Photo Illustration by Thomas Fuller/SOPA Images/LightRocket via Getty Images)SOPA Images/LightRocket via Getty ImagesMoonLake Immunotherapeutics (NASDAQ: MLTX), a biopharmaceutical firm in the clinical stage, experienced substantial fluctuations last week. The stock climbed 10% on Friday, September 26, as investors expected favorable outcomes from Phase 3 trials of son ...